Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00283101 · ClinicalTrials.gov registry record · Phase 1
A Safety Study in Patients With Chronic Lymphocytic Leukemia
A Phase 1 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00283101 is a Phase 1 study that has completed, run by Seagen. The registered enrollment target is 12 participants.
The verdict
NCT00283101, a Phase 1 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is an open-label, dose-escalation study to determine the tolerability, safety profile, and antitumor activity of SGN-40 in patients with CLL. All patients will receive dose escalation during the first two weeks regardless of cohort designation.
Interventions
- DRUG SGN-40 (anti-huCD40 mAb)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2005-07 |
| Est. Completion | 2006-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00283101
The ClinicalTrials.gov registry entry for NCT00283101 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SGN-40 (anti-huCD40 mAb) is the first listed.
NCT00283101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00283101 about?
NCT00283101 is a clinical study titled "A Safety Study in Patients With Chronic Lymphocytic Leukemia". This is an open-label, dose-escalation study to determine the tolerability, safety profile, and antitumor activity of SGN-40 in patients with CLL. All patients will receive dose escalation during the first two weeks regardless of cohort designation.
What is the current status of trial NCT00283101?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2005-07. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00283101?
The interventions under investigation include: SGN-40 (anti-huCD40 mAb) (DRUG).
Who is sponsoring clinical trial NCT00283101?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.